<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39195849</PMID><DateRevised><Year>2024</Year><Month>08</Month><Day>31</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2226-4787</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>4</Issue><PubDate><Year>2024</Year><Month>Jul</Month><Day>31</Day></PubDate></JournalIssue><Title>Pharmacy (Basel, Switzerland)</Title><ISOAbbreviation>Pharmacy (Basel)</ISOAbbreviation></Journal><ArticleTitle>Risk Characterization in Patients Using Benzodiazepines While Providing Pharmaceutical Care Dispensing Service.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">120</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/pharmacy12040120</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Tolerance and dependence stand out as the most relevant risks observed during benzodiazepine (BZD) treatments.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To evaluate the degree of dependence of patients on BZD treatments using the Tyrer test; to define a profile of patients at risk of developing BZD dependence; and to discuss the role of the pharmaceutical care offered by the community pharmacy during dispensing.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Prospective cross-sectional descriptive observational study (August 2020-February 2021) involving 127 patients using BZD. They voluntarily answered a questionnaire during the dispensing pharmaceutical care service. The study was evaluated and codified (code: DAA-CLO-2020-01) by the Spanish Agency for Drugs and Health Products (AEMPS), and statistical analysis was performed with SPSS 25.0.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">19.05% of patients using BZD were suspected of suffering from BZD tolerance, and 77.88% of all patients were identified as being at a high risk of BZD dependence. The Tyrer test for dependence indicated a mean score of 5.59 out of 13 points. An 18-fold increased risk of developing dependence was detected in the case of coexistence of high anxiety or depression.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The community pharmacy, through protocolized care practices and supported by tools such as the Tyrer test, can play a decisive role in the detection, prevention, and resolution of the risks associated with BZD treatments.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alberto Armas</LastName><ForeName>Daida</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-2481-7405</Identifier><AffiliationInfo><Affiliation>Research Group on Environmental Toxicology and Food and Drug Safety, University of La Laguna, Ofra, 38071 Canary Island, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hernández García</LastName><ForeName>Verónica</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0003-1272-4850</Identifier><AffiliationInfo><Affiliation>Research Group on Environmental Toxicology and Food and Drug Safety, University of La Laguna, Ofra, 38071 Canary Island, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Román Castillo</LastName><ForeName>Yanira</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Nursing Area of the Hospital Nuestra Señora de la Candelaria in Santa Cruz de Tenerife, 38010 Canary Islands, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santana Ayala</LastName><ForeName>Juan Ramón</ForeName><Initials>JR</Initials><Identifier Source="ORCID">0009-0007-6877-9734</Identifier><AffiliationInfo><Affiliation>Research Group on Environmental Toxicology and Food and Drug Safety, University of La Laguna, Ofra, 38071 Canary Island, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Capdevila Finestres</LastName><ForeName>Franc</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Research Group on Environmental Toxicology and Food and Drug Safety, University of La Laguna, Ofra, 38071 Canary Island, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hardisson de la Torre</LastName><ForeName>Arturo</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Research Group on Environmental Toxicology and Food and Drug Safety, University of La Laguna, Ofra, 38071 Canary Island, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rubio Armendáriz</LastName><ForeName>Carmen</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-8774-5870</Identifier><AffiliationInfo><Affiliation>Research Group on Environmental Toxicology and Food and Drug Safety, University of La Laguna, Ofra, 38071 Canary Island, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>07</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Pharmacy (Basel)</MedlineTA><NlmUniqueID>101678532</NlmUniqueID><ISSNLinking>2226-4787</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Tyrer test</Keyword><Keyword MajorTopicYN="N">benzodiazepines</Keyword><Keyword MajorTopicYN="N">community pharmacy</Keyword><Keyword MajorTopicYN="N">dependence</Keyword><Keyword MajorTopicYN="N">pharmaceutical care</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>7</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>28</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>28</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>28</Day><Hour>10</Hour><Minute>36</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>7</Month><Day>31</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39195849</ArticleId><ArticleId IdType="pmc">PMC11359597</ArticleId><ArticleId IdType="doi">10.3390/pharmacy12040120</ArticleId><ArticleId IdType="pii">pharmacy12040120</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gravielle M.C. Activation-induced regulation of GABAA receptors: Is there a link with the molecular basis of benzodiazepine tolerance? Pharmacol. Res. 2016;109:92–100. doi: 10.1016/j.phrs.2015.12.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2015.12.030</ArticleId><ArticleId IdType="pubmed">26733466</ArticleId></ArticleIdList></Reference><Reference><Citation>Foitzick M.F., Medina N.B., Iglesias García L.C., Gravielle M.C. Benzodiazepine exposure induces transcriptional down-regulation of GABAA receptor α1 subunit gene via L-type voltage-gated calcium channel activation in rat cerebrocortical neurons. Neurosci. Lett. 2020;721:134801. doi: 10.1016/j.neulet.2020.134801.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2020.134801</ArticleId><ArticleId IdType="pubmed">32007495</ArticleId></ArticleIdList></Reference><Reference><Citation>Vicente Sánchez M.P., Macías Saint-Gerons D., de la Fuente Honrubia C., González Bermejo D., Montero Corominas D., Catalá-López F. Evolución del uso de medicamentos ansiolíticos e hipnóticos en España durante el período 2000–2011. Rev. Esp. Salud Pública. 2013;87:3. doi: 10.4321/S1135-57272013000300004.</Citation><ArticleIdList><ArticleId IdType="doi">10.4321/S1135-57272013000300004</ArticleId><ArticleId IdType="pubmed">23892676</ArticleId></ArticleIdList></Reference><Reference><Citation>Gili M., García Campayo J., Roca M. Crisis económica y salud mental. Informe SESPAS 2014.  [(accessed on 25 May 2024)];Gac. Sanit. 2014 28((Suppl. S1)):104–108. doi: 10.1016/j.gaceta.2014.02.005. Available online:  https://www.gacetasanitaria.org/es-crisis-economica-salud-mental-informe-articulo-S0213911114000454.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gaceta.2014.02.005</ArticleId><ArticleId IdType="pubmed">24661346</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurlé M.A., Monti J., Flórez J. In: Fármacos Ansiolíticos y Sedantes. Farmacología de los Trastornos del Sueño. 6th ed. Flórez J., editor. Elsevier Masson; Barcelona, Spain: 2014. p. 447465.</Citation></Reference><Reference><Citation>Bertram G., Katzung M.D. Farmacología Básica y Clínica. McGraw Hill; Madrid, Spain: 2019. pp. 373–388.</Citation></Reference><Reference><Citation>Toral-López I., Moreno-Arco A., Cruz Vela P., Moratalla-López E., Domínguez-Martín S., Expósito-Ruíz M. Análisis de consumo de ansiolíticos e hipnóticos en un centro de atención primaria.  [(accessed on 25 May 2024)];Med. Fam. Andal. 2019 20:21–28. Available online:  https://www.samfyc.es/wp-content/uploads/2019/08/v20n1_O_analisisDeConsumo.pdf.</Citation></Reference><Reference><Citation>Minaya O., Ugalde O., Fresán A. Uso inapropiado de fármacos de prescripción: Dependencia a benzodiazepinas en adultos mayores. Salud Ment. 2009;32:405–411.</Citation></Reference><Reference><Citation>Mataud Aznar M.P., García Pérez L., Bethencourt Pérez M.l., Rodríguez-Wangüemert C. Género y uso de medicamentos ansiolíticos e hipnóticos en España. J. Fem. Gend. Women Stud. 2017;5:23–31.</Citation></Reference><Reference><Citation>Velert Vila J., Velert Vila M.M., Salar Ibáñez L., Avellana Zaragoza J.A., Moreno Royo L. Adecuación de la utilización de benzodiacepinas en ancianos desde la oficina de farmacia. Un estudio de colaboración médico- farmacéutico.  [(accessed on 25 May 2024)];Aten. Primaria. 2012 44:402–410. doi: 10.1016/j.aprim.2011.07.018. Available online:  https://www.sciencedirect.com/science/article/pii/S0212656711004331?via%3Dihub.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.aprim.2011.07.018</ArticleId><ArticleId IdType="pmc">PMC7025934</ArticleId><ArticleId IdType="pubmed">22023889</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubio Armendáriz C. Benzodiazepines Drug Consumption Trends in a Community Pharmacy. Assessment of the Dispensed Daily Dose. EC Pharmacol. Toxicol. 2020;8:1–9.</Citation></Reference><Reference><Citation>Alberto Armas D., Rubio Armendáriz C., Hernández García V., Hardisson de la Torre A. Cuestionario específico para dispensación de Benzodiacepinas en Farmacia Comunitaria. JONNPR. 2023;8:450–469. doi: 10.19230/jonnpr.4721.</Citation><ArticleIdList><ArticleId IdType="doi">10.19230/jonnpr.4721</ArticleId></ArticleIdList></Reference><Reference><Citation>Alberto Armas D., Santana Ayala J.R., Román Castillo Y., Hardisson de la Torre A., Rubio Armendáriz C. Quality of Life Assessment in Patients Using Benzodiazepines during the COVID-19 Pandemic in a Community Pharmacy Using EuroQol 5D-3L. Pharmacy. 2023;11:19. doi: 10.3390/pharmacy11010019.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmacy11010019</ArticleId><ArticleId IdType="pmc">PMC9959496</ArticleId><ArticleId IdType="pubmed">36827657</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreri M.C., Gutiérrez M.L., Gravielle M.C. Tolerance to the sedative and anxiolytic effects of diazepam is associated with different alterations of GABAA receptors in rat cerebral cortex. Neuroscience. 2015;310:152–162. doi: 10.1016/j.neuroscience.2015.09.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2015.09.038</ArticleId><ArticleId IdType="pubmed">26391922</ArticleId></ArticleIdList></Reference><Reference><Citation>Ana L.V., Alina A.A., Jamet B.R., Nelaines O.F. Uso y Abuso de las Benzodiazepinas. MEDISAN. 2010.  [(accessed on 25 May 2024)].  Available online:  http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S1029-30192010000400017&amp;lng=es.</Citation></Reference><Reference><Citation>Busto U.E., Bremner K.E., Knight K., terBrugge K., Sellers E.M. Long-term benzodiazepine therapy does not result in brain abnormalities. J. Clin. Psychopharmacol. 2000;20:2–6. doi: 10.1097/00004714-200002000-00002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00004714-200002000-00002</ArticleId><ArticleId IdType="pubmed">10653201</ArticleId></ArticleIdList></Reference><Reference><Citation>Hood S.D., Norman A., Hince D.A., Melichar J.K., Hulse G.K. Benzodiazepine dependence and its treatment with low dose flumazenil. Br. J. Clin. Pharmacol. 2014;77:285–294. doi: 10.1111/bcp.12023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bcp.12023</ArticleId><ArticleId IdType="pmc">PMC4014019</ArticleId><ArticleId IdType="pubmed">23126253</ArticleId></ArticleIdList></Reference><Reference><Citation>Itzel R.-G., Karina S.-A., Francisco M. Mecanismo celular y molecular de la adicción a benzodiacepinas Salud Mental, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz Distrito Federal, México. Salud Ment. 2013;36:325–329.</Citation></Reference><Reference><Citation>Tyrer P. ABC of sleep disorders: Withdrawal from hypnotic drugs. BMJ. 1993;306:706–708. doi: 10.1136/bmj.306.6879.706.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.306.6879.706</ArticleId><ArticleId IdType="pmc">PMC1677114</ArticleId><ArticleId IdType="pubmed">8471930</ArticleId></ArticleIdList></Reference><Reference><Citation>Lader M., Tylee A., Donoghue J. Withdrawing benzodiazepines in primary care. CNS Drugs. 2009;23:19–34. doi: 10.2165/0023210-200923010-00002.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/0023210-200923010-00002</ArticleId><ArticleId IdType="pubmed">19062773</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng L., Morford K.L., Levander X.A. Benzodiazepines and Related Sedatives. Med. Clin. N. Am. 2022;106:113–129. doi: 10.1016/j.mcna.2021.08.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcna.2021.08.012</ArticleId><ArticleId IdType="pubmed">34823725</ArticleId></ArticleIdList></Reference><Reference><Citation>Guina J., Merrill B. Benzodiazepines I: Upping the care on downers: The evidence of risks, benefits and alternatives. J. Clin. Med. 2018;7:17. doi: 10.3390/jcm7020017.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm7020017</ArticleId><ArticleId IdType="pmc">PMC5852433</ArticleId><ArticleId IdType="pubmed">29385731</ArticleId></ArticleIdList></Reference><Reference><Citation>Observatorio de Uso de Medicamentos  Informe de Utilización de Medicamentos. Utilización de Medicamentos Ansiolíticos e Hipnóticos en España Durante el Periodo 2010–2021 Agencia Española de Medicamentos y Productos Sanitarios (AEMPS)  [(accessed on 25 May 2024)]; Available online:  https://www.aemps.gob.es/medicamentos-de-uso-humano/observatorio-de-uso-de-medicamentos/</Citation></Reference><Reference><Citation>JIFE  Informe Anual de la Junta Internacional de Fiscalización de Estupefacientes. 2021.  [(accessed on 25 May 2024)].  Available online:  https://www.incb.org/incb/es/publications/annual-reports/annual-report.html.</Citation></Reference><Reference><Citation>Foro de Atención Farmacéutica-Farmacia Comunitaria (Foro AF-FC), Panel de Expertos  Guía Práctica para los Servicios Profesionales Farmacéuticos Asistenciales desde la Farmacia Comunitaria. Madrid: Consejo General de Colegios Oficiales de Farmacéuticos. 2024.  [(accessed on 25 May 2024)].  Available online:  https://www.farmaceuticos.com/farmaceuticos/farmacia/farmacia-asistencial/foro-de-atencion-farmaceutica/</Citation></Reference><Reference><Citation>Morris C., McDonald J., Officer T.N., Tanuvasa A.F., Smiler K., Parore N., Dunn P., McKinlay E., Kennedy J., McBride-Henry K., et al. A realist evaluation of the development of extended pharmacist roles and services in community pharmacies. Res. Soc. Adm. Pharm. 2024;20:321–334. doi: 10.1016/j.sapharm.2023.11.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sapharm.2023.11.006</ArticleId><ArticleId IdType="pubmed">38065764</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhalimi M., Rauss A., Housieaux E. Drug-related problems identified during geriatric medication review in the community pharmacy. Int. J. Clin. Pharm. 2018;40:109–118. doi: 10.1007/s11096-017-0571-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11096-017-0571-y</ArticleId><ArticleId IdType="pubmed">29188412</ArticleId></ArticleIdList></Reference><Reference><Citation>Mongaret C., Aubert L., Lestrille A., Albaut V., Kreit P., Herlem E., Noel N., Touré F., Lallier F., Slimano F., et al. The Role of Community Pharmacists in the Detection of Clinically Relevant Drug-Related Problems in Chronic Kidney Disease Patients. Pharmacy. 2020;8:89. doi: 10.3390/pharmacy8020089.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmacy8020089</ArticleId><ArticleId IdType="pmc">PMC7355920</ArticleId><ArticleId IdType="pubmed">32456115</ArticleId></ArticleIdList></Reference><Reference><Citation>Ylä-Rautio H., Siissalo S., Leikola S. Drug-related problems and pharmacy interventions in non-prescription medication, with a focus on high-risk over-the-counter medications. Int. J. Clin. Pharm. 2020;42:786–795. doi: 10.1007/s11096-020-00984-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11096-020-00984-8</ArticleId><ArticleId IdType="pmc">PMC7192881</ArticleId><ArticleId IdType="pubmed">32078108</ArticleId></ArticleIdList></Reference><Reference><Citation>Alghamdi K.S., Petzold M., Alsugoor M.H., Makeen H.A., Al Monif K.H., Hussain-Alkhateeb L. Community pharmacists’ perspectives towards automated pharmacy systems and extended community pharmacy services: An online cross-sectional study. Explor. Res. Clin. Soc. Pharm. 2023;12:100363. doi: 10.1016/j.rcsop.2023.100363.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rcsop.2023.100363</ArticleId><ArticleId IdType="pmc">PMC10679933</ArticleId><ArticleId IdType="pubmed">38023630</ArticleId></ArticleIdList></Reference><Reference><Citation>Balestroni G., Bertolotti G. L’EuroQol-5D (EQ-5D): Uno strumento per la misura della qualità della vita [EuroQol-5D (EQ-5D): An instrument for measuring quality of life] Monaldi Arch. Chest Dis. 2012;78:155–159. doi: 10.4081/monaldi.2012.121. (In Italian)</Citation><ArticleIdList><ArticleId IdType="doi">10.4081/monaldi.2012.121</ArticleId><ArticleId IdType="pubmed">23614330</ArticleId></ArticleIdList></Reference><Reference><Citation>Little M.H., Reitmeir P., Peters A., Leidl R. The impact of differences between patient and general population EQ-5D-3L values on the mean tariff scores of different patient groups. Value Health. 2014;17:364–371. doi: 10.1016/j.jval.2014.02.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jval.2014.02.002</ArticleId><ArticleId IdType="pubmed">24968996</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfeiffer E. A short portable mental status questionnaire for the assessment of organic brain deficit in elderly patients. J. Am. Geriatr. Soc. 1975;23:433–441. doi: 10.1111/j.1532-5415.1975.tb00927.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1532-5415.1975.tb00927.x</ArticleId><ArticleId IdType="pubmed">1159263</ArticleId></ArticleIdList></Reference><Reference><Citation>Gómez S., León T., Macuera M., Alves M., Ruiz S. Uso de benzodiazepinas en adultos mayores en América Latina. Rev. Med. Chile. 2017;145:351–359. doi: 10.4067/S0034-98872017000300009.</Citation><ArticleIdList><ArticleId IdType="doi">10.4067/S0034-98872017000300009</ArticleId><ArticleId IdType="pubmed">28548192</ArticleId></ArticleIdList></Reference><Reference><Citation>Schommer J.C., Pedersen C.A., Gaither C.A., Doucette W.R., Kreling D.H., Mott D.A. Pharmacists’ Desired and Actual Times in Work Activities: Evidence of Gaps from the 2004 National Pharmacist Workforce Study. J. Am. Pharm. Assoc. 2006;46:340–347. doi: 10.1331/154434506777069606.</Citation><ArticleIdList><ArticleId IdType="doi">10.1331/154434506777069606</ArticleId><ArticleId IdType="pubmed">16739755</ArticleId></ArticleIdList></Reference><Reference><Citation>Gastelurrutia M.A., Fernandez-Llimos F. Dispensación. Aula Farm. 2004;1:9–26.</Citation></Reference><Reference><Citation>Villa R.S., García E.R., Barbero J.V., Hermida J.R.F., Seco G.V., García J.M.J. El consumo de psicofármacos en pacientes que acuden a Atención Primaria en el Principado de Asturias (España) Use of psychoactive drugs in patients attending GPs’ surgeries in the Principality of Asturias (Spain) Psicothema. 2003;15:650–655.</Citation></Reference><Reference><Citation>De la Cruz Godoy M.J., Herrera Fariñas A., González M.T., Bárbara Fariñas M., Egea Molina E. Adicciones Ocultas: Aproximación al Consumo Diferencial de Psicofármacos. Investigación Promovida y Financiada por el Fondo Social Europeo y el Instituto Canario de la Mujer; Diseñada y Realizada por el Colegio oficial de Psicólogos de Las Palmas y Fundación Canaria para la Prevención e Investigación de las Drogodependencias (FUNCAPID) Consejería de Sanidad, Gobierno de Canarias; Las Palmas, Spain: 2008.</Citation></Reference><Reference><Citation>American Psychiatric Association . Diagnostic and Statistic Manual of Mental Disorder. 5th ed. American Psychiatric Association; Washington, DC, USA: 2002.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>